924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Amgen and Kyowa Kirin signed a Termination Agreement on January 30, 2026, to end their License and Collaboration Agreement dated June 1, 2021. The termination takes effect only after regulatory approval is received, and the filing gives no financial terms or reasons.
Termination Agreement dated January 30, 2026 with Kyowa Kirin Co., Ltd.
Ends the License and Collaboration Agreement dated June 1, 2021
Termination is effective upon receipt of regulatory approval
Agreement filed as Exhibit 10.1; portions omitted as not material
Delta Air Lines signed a definitive agreement on January 27, 2026 to buy 16 Airbus A330-900 and 15 Airbus A350-900 aircraft, with an option for up to 20 more widebody aircraft. The filing says the order is within Delta's previously announced capital expenditure and capacity targets and that Delta has obtained long-term financing for a substantial portion of each aircraft's purchase price.
Firm order: 16 Airbus A330-900 aircraft and 15 Airbus A350-900 aircraft
Option to buy up to an additional 20 widebody aircraft
Deliveries begin in 2029; A330-900 uses Rolls-Royce Trent 7000 engines, A350-900 uses Trent XWB-84 EP engines
Order is within previously announced capital expenditure and capacity targets; long-term financing obtained for a substantial portion of the purchase price
Amphastar entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology on January 6, 2026, for AMP-110, a fully synthetic corticotropin compound in early-phase human clinical development, covering the United States and Canada. Hanxin is controlled by family members of Amphastar's CEO and Chairman, so the agreement and two related amendments are related party transactions, and the company says the amendments are not expected to be material.
Amphastar made a $2 million upfront payment to Hanxin, with up to $14 million in development milestones and up to $75 million in sales milestones.
Royalties payable by Amphastar to Hanxin are capped at $7.5 million per calendar year and $60 million in total accumulated.
Dr. Jack Zhang and Dr. Mary Luo and certain family members own a majority of Hanxin; the Audit Committee approved the distribution and manufacturing amendments.
The Distribution and Manufacturing Amendments expand territories; their value is not determinable until sales occur in the expanded regions.
Alaska Airlines finalized an order with Boeing for 53 incremental 737-10 aircraft and exercised 52 737-10 options, plus five 787 options, all dated December 31, 2025. The company also added options for 35 more 737-10 aircraft, and the filing does not disclose a purchase price. The deliveries extend Alaska's aircraft delivery stream through 2035 and support its fleet growth plans.
53 incremental and 52 option 737-10 aircraft scheduled for delivery between 2028 and 2035
Five 787 option aircraft exercised for delivery between 2031 and 2032
35 additional 737-10 option aircraft added to the purchase agreement
Company plans to file the supplemental agreements with its 2025 Form 10-K
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.